Delivery Order SPE2DB22D1017-SPE2DB25FYRRW
Award Date 9/23/25
Potential Completion Date 9/24/25
Potential Value $4.3K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order valued at $13,306.04 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pens on August 11, 2025, with an ultimate completion date of August 12, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Zepbound is a semaglutide injection used for weight management in adults with obesity or...
- The Defense Logistics Agency awarded a $13,859.30 delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pens on July 30, 2025, with an ultimate completion date of July 31, 2025. This competitively awarded, firm fixed-price contract includes no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Zepbound is a semaglutide-based medication used for weight management, representing part of the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,572.90 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pen injectors on September 10, 2025, with completion scheduled for September 11, 2025. This firm fixed-price delivery order was competitively awarded without any set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Zepbound is a semaglutide-based obesity treatment medication, reflecting the federal...
- The Defense Logistics Agency awarded a delivery order valued at $4,752.44 to AmerisourceBergen Drug Corp for the supply of Zepbound 10 mg/0.5 mL pens on April 28, 2025, with an ultimate completion date of April 29, 2025. The contract utilizes firm fixed price pricing and was competitively awarded without set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Zepbound 15 mg/0.5 mL pens valued at $3,812.98. This is a firm fixed-price delivery order with an ultimate completion date of August 12, 2025, and will be performed at the vendor's facility in Conshohocken, Pennsylvania. The award was made without a set-aside designation, indicating it was competitively awarded. Zepbound is a semaglutide-based medication used for weight...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $33,963.10 to AmerisourceBergen Drug Corp for the supply of Zepbound 10 mg/0.5 mL pens on August 7, 2025, with completion expected by August 8, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist used for weight management and represents part of the...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injections with a ceiling value of $4,466.38. This is a firm fixed price delivery order under a competitive, non-set-aside procurement. The contract is set to be completed by August 8, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound (semaglutide) is a GLP-1 receptor...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $30,103.40 for Zepbound 7.5 mg/0.5 mL pens on July 21, 2025, with an ultimate completion date of July 22, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania location. Zepbound is a semaglutide-based medication indicated for weight management and represents part of the pharmaceutical...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $5,973.24 on July 31, 2025, for the supply of Zepbound 5 mg/0.5 mL pens (0.5 mL). This is a firm fixed-price delivery order with no set-aside designation, issued as a child contract under AmerisourceBergen's larger pharmaceutical supply agreement. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, with completion scheduled for August 1, 2025. Zepbound, a semaglutide...
- The Defense Logistics Agency awarded a $2,594.37 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pens with an ultimate completion date of September 5, 2025. Zepbound is a semaglutide-based medication indicated for weight management and diabetes treatment. This non-set-aside award was competitively procured and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery...